Brexogen's Exosome Therapy for Atopic Dermatitis, 'BRE-AD01' Accepted for Phase 1 Clinical Trials by US FDA
PR98596
SEOUL, South Korea, Nov. 7, 2022 /PRNewswire=KYODO JBN/ --
First entry to clinical trial of exosome for atopic dermatitis
The first exosome-based therapeutics in US clinical trial among Korean companies
The US FDA granted the initiation of the phase 1 clinical trial of 'BRE-AD01',
an exosome- based therapy for atopic dermatitis. 'BRE-AD01' is being developed
by Brexogen with its own exosome-platform technology. It is the first phase 1
clinical trial of therapeutic exosome for atopic dermatitis in major countries.
This IND clearance is very meaningful in that patients with atopic dermatitis
can benefit from receiving better treatment with 'BRE-AD01', which is armed
with multiple mode of action.
'BRE-AD01' is produced from stem cells (named 'BxC') stimulated with a
specified, well-defined clinical available compound, which comprised the
backbone of Brexogen's technology. In various preclinical models, superior
therapeutic effects were demonstrated by BRE-AD01 compared to competing drugs
(Dupixent, JAK inhibitors, steroids). Recently, serious side effects have been
reported by patients that received JAK inhibitor, which was approved as an
innovative drug for the atopic dermatitis. In contrast, no side effect was
observed in BRE-AD0-received atopic dermatitis animals, with better therapeutic
efficacy. BRE-AD01 has multiple MOAs (such as repressing type 2 immune
reaction, regulating IL-31R, and promoting skin barrier recovery, contributing
to enhanced atopic dermatitis symptoms.
According to Brexogen Inc. on October 27, the Center for Biologics Evaluation
and Research (CBER), US FDA, completed the review of phase 1 clinical trial for
BRE-AD01 and confirmed the starting of the phase 1 clinical trial.
In this clinical trial, patients with severe atopic dermatitis will receive
BRE-AD01, and the safety and therapeutic efficacy of IGA, EASI, and SCORAD will
be evaluated as well.
Dr. Soo Kim, the CEO and co-founder of Brexogen Inc. said, "I am very happy to
hear our Phase 1 clinical trial was accepted by the US FDA. Conducting the
first clinical study on an exosome therapeutics developed from South Korea has
an important meaning in that the potential of exosome technology, which is
currently at the research level, can be greatly improved to a level that can be
commercialized as a reliable option. We will use our stem cell priming strategy
to accelerate the development of next pipeline using the results from this
clinical trial. After successful completion Phase 1 trial, we will conduct
follow-up clinical trials with the patients. However, exosome therapy is still
facing difficulties in development, but can be commercialized at a global level
once we overcome these issues (such as quality control and manufacturing
process). We will continue to provide a therapeutic exosome for several
indications."
Dr. Kim said, "We are making efforts to commercialize not only pharmaceuticals
but also various products using exosomes with different ingredients developed
through the Brexogen exosome platform technology. Starting from this clinical
trial, we will continue developing exosome products."
[Introduction] www.brexogen.com
Brexogen is a company established in 2019 by CEO Soo Kim, who has expertise in
stem cells and exosomes for more than 20 years. She established the BG-Platform
technology for developing exosome therapeutics to overcome the limitations of
current exosome therapeutics in quality control and mass production.
BG-Platform technology utilizes the therapeutic cargo-controlled exosome
optimized for various diseases such as atopic dermatitis (BRE-AD01), myocardial
infarction (BRE-MI01), and non-alcoholic fatty hepatitis (BRE-NA01).
Source: Brexogen
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。